Similar articles

• List of drugs in development for neurodegenerative diseases. Update June 2004.

  Kwon MO, Fischer F, Matthisson M, Herrling P. Kwon MO, et al. Neurodegener Dis. 2004;1(2-3):113-52. doi: 10.1159/000081242. Neurodegener Dis. 2004. PMID: 16908983 No abstract available.
• [Risperdal: a new hope for schizophrenic patients?].

  [No authors listed] [No authors listed] Fortschr Neurol Psychiatr. 1994 May;62(5 Suppl):1-4. Fortschr Neurol Psychiatr. 1994. PMID: 9131061 German. No abstract available.
• Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.

  Kuroki T, Nagao N, Nakahara T. Kuroki T, et al. Prog Brain Res. 2008;172:199-212. doi: 10.1016/S0079-6123(08)00910-2. Prog Brain Res. 2008. PMID: 18772034 Review.
• List of drugs in development for neurodegenerative diseases. Update June 2007.

  Pogacić V, Herrling P. Pogacić V, et al. Neurodegener Dis. 2007;4(6):443-86. doi: 10.1159/000107705. Neurodegener Dis. 2007. PMID: 17934328 No abstract available.
• [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)].

  Kudo T. Kudo T. Seishin Shinkeigaku Zasshi. 2007;109(7):657-63. Seishin Shinkeigaku Zasshi. 2007. PMID: 17969953 Review. Japanese. No abstract available.